Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRMT5 | O14744 | 15/20 | 0.47 |
| ▸ | WDR77 | Q9BQA1 | 11/20 | 0.47 |
| ▸ | METTL3 | Q86U44 | 3/20 | 0.38 |
| ▸ | METTL14 | Q9HCE5 | 1/20 | 0.38 |
| ▸ | ADK | P55263 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23584858 | 0.95 | PRMT5 (0.48) | PRMT5WDR77METTL3METTL14ADK | |
| SCHEMBL23584738 | 0.89 | PRMT5 (0.51) | PRMT5WDR77METTL3METTL14ADK | |
| SCHEMBL23584873 | 0.88 | PRMT5 (0.51) | PRMT5WDR77METTL3METTL14ADK | |
| SCHEMBL23584634 | 0.87 | PRMT5 (0.47) | PRMT5WDR77METTL3METTL14ADK | |
| SCHEMBL23584531 | 0.87 | PRMT5 (0.46) | PRMT5WDR77METTL3METTL14ADK | |
| SCHEMBL23584475 | 0.85 | PRMT5 (0.40) | PRMT5WDR77METTL3METTL14 | |
| SCHEMBL23584804 | 0.84 | PRMT5 (0.54) | PRMT5WDR77METTL3METTL14MEN1 | |
| SCHEMBL23584701 | 0.84 | ADK (0.46) | PRMT5WDR77METTL3ADKMEN1 | |
| SCHEMBL19344291 | 0.84 | PRMT5 (0.42) | PRMT5WDR77METTL3ADKMEN1 | |
| SCHEMBL23584833 | 0.83 | PRMT5 (0.45) | PRMT5WDR77METTL3METTL14ADK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3426664-B1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2021-06-30 | — | — | EP | disclosed |
| WO-2017153186-A1 | SUBSTITUTED NUCLEOSIDE ANALOGUES FOR USE AS PRMT5 INHIBITORS | JANSSEN PHARMACEUTICA NV (BE) | 2017-09-14 | — | — | WO | disclosed |